Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immucell (ICCC) Cash from Operations (2016 - 2025)

Immucell (ICCC) has disclosed Cash from Operations for 16 consecutive years, with 1182583.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash from Operations fell 84.97% year-over-year to 1182583.0, compared with a TTM value of 1989700.0 through Sep 2025, up 649.46%, and an annual FY2024 reading of 357903.0, up 107.66% over the prior year.
  • Cash from Operations was 1182583.0 for Q3 2025 at Immucell, down from 1601498.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 1601498.0 in Q2 2025 and bottomed at 2761985.0 in Q1 2023.
  • Average Cash from Operations over 5 years is 153330.68, with a median of 3051.0 recorded in 2024.
  • The sharpest move saw Cash from Operations soared 276.26% in 2021, then crashed 585.75% in 2022.
  • Year by year, Cash from Operations stood at 587893.0 in 2021, then tumbled by 320.76% to 1297822.0 in 2022, then soared by 44.29% to 723071.0 in 2023, then surged by 99.58% to 3051.0 in 2024, then plummeted by 38660.5% to 1182583.0 in 2025.
  • Business Quant data shows Cash from Operations for ICCC at 1182583.0 in Q3 2025, 1601498.0 in Q2 2025, and 1573836.0 in Q1 2025.